To read the full story, subscribe or sign in.

Remegen pockets $100M in private funding to advance lupus drug

April 14, 2020

BEIJING – China, Yantai-based biologics maker Remegen Ltd. has raised about $100 million in a private round led by Lilly Asia Ventures and Lake Bleu Capital.

BioWorld Asia Financings Immune Private

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 16, 2025.

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.

Woman in military clothing talking with psychologist

FDA wants more data for Otsuka’s sNDA in PTSD

BioWorld

The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...